13.39
13.39 (0%)
As of Feb 14, 2025
Inhibrx, Inc. [INBX]
Source:
Company Overview
Inhibrx, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms.
| Country | United States |
| Headquarters | la jolla, california |
| Phone Number | (858) 795-4220 |
| Industry | manufacturing |
| CEO | Mark P. Lappe |
| Website | www.inhibrx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.8 |
| Operating Profit | $-219.2 |
| Net Income | $-241.4 |
| Net Cash | $4.1 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -12,178.9 |
| Profit as % of Revenues | |
| Profit as % of Assets | -80.6% |
| Profit as % of Stockholder Equity | -554.8% |
Management Effectiveness
| Return on Equity | 0% |
| Return on Assets | 0% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $307.9 |
| Total Liabilities | $264.4 |
| Operating Cash Flow | $-193.3 |
| Investing Cash Flow | $-4.6 |
| Financing Cash Flow | $202 |
